

HLA-DR/DP (MEM-136): sc-51618

BACKGROUND

Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4⁺ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in MHC II- α/β dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane-anchored heavy chain and a light chain (β -2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.

REFERENCES

- Horejsi, V., et al. 1986. Characterization of seven new monoclonal antibodies against human DR, DR + DP and DQ1 + DQ3 antigens. *Tissue Antigens* 28: 288-297.
- Horejsi, V., et al. 1986. Monoclonal antibodies against human leucocyte antigens. I. Antibodies against β -2-Microglobulin, immunoglobulin κ light chains, HLA-DR-like antigens, T8 antigen, T1 antigen, a monocyte antigen and a pan-leucocyte antigen. *Folia Biol.* 32: 12-25.
- Kropshofer, H., et al. 1998. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. *EMBO J.* 17: 2971-2981.
- Siegmund, T., et al. 1999. HLA-DMA and HLA-DMB alleles in German patients with type 1 diabetes mellitus. *Tissue Antigens* 54: 291-294.
- Arndt, S.O., et al. 2000. Functional HLA-DM on the surface of B cells and immature dendritic cells. *EMBO J.* 19: 1241-1251.
- Brunet, A., et al. 2000. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DO β . *J. Biol. Chem.* 275: 37062-37071.

SOURCE

HLA-DR/DP (MEM-136) is a mouse monoclonal antibody raised against PHA-activated peripheral blood lymphocytes of human origin.

PRODUCT

Each vial contains 100 μ g IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

HLA-DR/DP (MEM-136) is available conjugated phycoerythrin (sc-51618 PE, 100 tests in 2 ml), for WB (RGB), IF, IHC(P) and FCM.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


APPLICATIONS

HLA-DR/DP (MEM-136) is recommended for detection of common epitope on β -chain of HLA-DR and HLA-DP, the α/β dimer and the dissociated β -subunit of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)] and flow cytometry (1 μ g per 1 x 10⁶ cells).


Molecular Weight of HLA-DR/DP β : 30/29 kDa.

Positive Controls: HuT 78 whole cell lysate: sc-2208, HLA-DR β 3 (h): 293T Lysate: sc-110914 or BJAB whole cell lysate: sc-2207.

DATA



HLA-DR/DP (MEM-136): sc-51618. Western blot analysis of HLA-DR β 1 expression in non-transfected 293T: sc-117752 (A), human HLA-DR β 1 transfected 293T: sc-115102 (B) and BJAB (C) whole cell lysates.



HLA-DR/DP (MEM-136): sc-51618. Western blot analysis of HLA-DR β 3 expression in non-transfected: sc-117752 (A) and human HLA-DR β 3 transfected: sc-110914 (B) 293T whole cell lysates.

SELECT PRODUCT CITATIONS

- Paggetti, J., et al. 2015. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. *Blood* 126: 1106-1117.
- Wierz, M., et al. 2019. Purification of leukemia-derived exosomes to study microenvironment modulation. *Methods Mol. Biol.* 1884: 231-245.
- Bordas, M., et al. 2020. Optimized protocol for isolation of small extracellular vesicles from human and murine lymphoid tissues. *Int. J. Mol. Sci.* 21: 5586.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.



See **HLA-DR (520B): sc-69673** for HLA-DR antibody conjugates, including AC, HRP, FITC, PE, and Alexa Fluor® 488, 546, 594, 647, 680 and 790.